US Drug Recall Register

FDA Drug Recalls

1,709 recalls · Class III, newest first

Class III · Low risk Terminated

Brimonidine Tartrate Opthalmic Solution 0.2%

Reason Failed Impurities/Degradation Specification: There is a slow leaching process from the product label on the bottle which may impact the product over the shelf life.

Somerset Therapeutics LLC NDC 70069-232-01 D-1374-2020
Class III · Low risk Terminated

Brimonidine Tartrate Opthalmic Solution 0.2%

Reason Failed Impurities/Degradation Specification: There is a slow leaching process from the product label on the bottle which may impact the product over the shelf life.

Somerset Therapeutics LLC NDC 70069-231-01 D-1373-2020
Class III · Low risk Terminated

Lamotrigine Tablets

Reason Presence of Foreign Substance consistent with granules from desiccant packs used during storage

AVKARE Inc. NDC 42291-368-60 D-1289-2020
Class III · Low risk Terminated

Duavee

Reason Failed Dissolution Specifications

Pfizer Inc. NDC 00008-1123-12 D-1342-2020
Class III · Low risk Terminated

Olanzapine Tablets

Reason Failed Impurities/ Degradation Specifications

Aurobindo Pharma USA Inc. NDC 66993-682-30 D-1315-2020
Class III · Low risk Terminated

Olanzapine Tablets

Reason Failed Impurities/ Degradation Specifications

Aurobindo Pharma USA Inc. NDC 66993-680-30 D-1314-2020
Class III · Low risk Terminated

Clonidine Hydrochloride Tablets

Reason Failed Impurities/Degradation Specifications: potential migration of benzophenone at very low level into the product from container.

Unichem Pharmaceuticals USA INC NDC 29300-135-01 D-1291-2020
Class III · Low risk Terminated

Lamotrigine Tablets

Reason Presence of Foreign Substance visually consistent with the silica granules present in the desiccant packs utilized during storage of the product.

Jubilant Cadista Pharmaceuticals, Inc. NDC 59746-247-97 D-1281-2020
Class III · Low risk Terminated

Zilretta

Reason Temperature Abuse: Product was stored at room temperature longer than 6 weeks and was inadvertently distributed instead of discarded

Flexion Therapeutics, Inc. NDC 70801-003-01 D-1376-2020
Class III · Low risk Terminated

Gabapentin Tablets USP

Reason Failed Impurities/Degradation Specifications; failure of Impurity A test at the 12-month long-term stability testing.

InvaGen Pharmaceuticals, Inc. NDC 76282-405-05 D-1272-2020
Class III · Low risk Terminated

Ethacrynic Acid Tablets USP

Reason Failed Impurities/Degradation Specifications: Out of Specification for impurity 6 and total degradants.

West-Ward Columbus Inc D-1282-2020
Class III · Low risk Terminated

Potassium Acetate Injection

Reason Short Fill

Exela Pharma Sciences LLC NDC 51754-2001-4 D-1585-2020
Class III · Low risk Terminated

Memantine Hydrochloride Extended-Release Capsules

Reason Failed dissolution specifications: Low stage 3 results obtained for dissolution during routine stability testing.

The Harvard Drug Group D-1262-2020
Class III · Low risk Terminated

R.E.C.K.

Reason Presence of Particulate Matter: Fresenius Kabi recalling vials of Ketorolac

QuVa Pharma, Inc. D-1335-2020
Class III · Low risk Terminated

Fentanyl Citrate Injection

Reason Failed impurities/degradation specification: Out-of-Specification result for total impurity at 4.1% (Limit: NMT 3.0%) during retained sample testing.

Akorn Inc NDC 17478-030-02 D-1258-2020
Class III · Low risk Terminated

Tacrolimus Capsules

Reason Presence of foreign tablet/capsule - Potential presence of commingled one Tacrolimus 1 mg capsule in 5 mg bottles.

Mylan Pharmaceuticals Inc. NDC 0378-2047-01 D-1057-2020
Class III · Low risk Terminated

Bekyree

Reason Failed Content Uniformity Specifications: Out Of Specification test results observed for content and blend uniformity.

Lupin Pharmaceuticals Inc. NDC 68180-879-11 D-1055-2020
Class III · Low risk Terminated

PrediniSONE Tablets

Reason Labeling: Incorrect or Missing Exp Date - An incorrect expiration date has been identified on Prednisone Tablets USP 5 mg

Par Pharmaceutical Inc. NDC 0603-5337-31 D-1035-2020
Class III · Low risk Terminated

Quetiapine Fumarate Extended-Release Tablets

Reason Labeling; Incorrect or Missing Package Insert: Product was packaged with the package insert for Quetiapine Fumarate Tablets not Quetiapine Fumarate Extended-Release Tablets.

The Harvard Drug Group D-1002-2020
Class III · Low risk Terminated

Quetiapine Fumarate Extended-Release Tablets

Reason Labeling; Incorrect or Missing Package Insert: Product was packaged with the package insert for Quetiapine Fumarate Tablets not Quetiapine Fumarate Extended-Release Tablets.

The Harvard Drug Group D-1001-2020
Class III · Low risk Terminated

Quetiapine Fumarate Extended-Release Tablets

Reason Labeling; Incorrect or Missing Package Insert: Product was packaged with the package insert for Quetiapine Fumarate Tablets not Quetiapine Fumarate Extended-Release Tablets.

The Harvard Drug Group D-1000-2020